A5064439128- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Viral Infectious Diseases and Gene Expression in Insects
- Glycosylation and Glycoproteins Research
- Ubiquitin and proteasome pathways
- Cancer Mechanisms and Therapy
- Immune cells in cancer
- Transgenic Plants and Applications
- Histone Deacetylase Inhibitors Research
- Nanowire Synthesis and Applications
- Immune Cell Function and Interaction
- Peptidase Inhibition and Analysis
- Microplastics and Plastic Pollution
- Retinoids in leukemia and cellular processes
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- Graphene and Nanomaterials Applications
- Virus-based gene therapy research
- Chronic Lymphocytic Leukemia Research
- Research on Leishmaniasis Studies
- vaccines and immunoinformatics approaches
- CRISPR and Genetic Engineering
- Single-cell and spatial transcriptomics
Kettering University
2023-2024
City Of Hope National Medical Center
2024
Memorial Sloan Kettering Cancer Center
2024
University of Wisconsin–Madison
2016-2023
University of Oxford
2023
Madison Group (United States)
2023
Center for Cancer Research
2020
Harvard University
2016
Brigham and Women's Hospital
2016
Carbon-based nanomaterials such as single-walled carbon nanotubes and reduced graphene oxide are currently being evaluated for biomedical applications including in vivo drug delivery tumor imaging. Several reports have studied the toxicity of nanomaterials, but their effects on human male reproduction not been fully examined. Additionally, it is clear whether nanomaterial exposure has any effect sperm sorting procedures used clinical settings. Here, we show that presence functionalized...
Previous studies indicate that Kras is dispensable for fetal liver hematopoiesis, but its role in adult hematopoiesis remains unclear. Here, we generated a conditional knockout allele to address this question. Deletion of bone marrow (BM) mediated by Vav-Cre or inducible Mx1-Cre. We find loss leads greatly reduced thrombopoietin (TPO) signaling hematopoietic stem cells (HSCs) and multipotent progenitors (MPPs), while cell factor-evoked ERK1/2 activation not affected. The compromised TPO...
Abstract Multiple myeloma (MM) is a malignant plasma cell cancer. Mutations in RAS pathway genes are prevalent advanced and proteasome inhibitor (PI) refractory MM. As such, we recently developed VQ MM mouse model recapitulating human advanced/high-risk Using lines conducted repurposing screen of 147 FDA-approved anti-cancer drugs with or without trametinib (Tra), MEK inhibitor. Consistent its high-risk molecular feature, displayed reduced responses to PIs de novo resistance the BCL2...
We previously demonstrated that a subset of acute myeloid leukemia (AML) patients with concurrent RAS pathway and TP53 mutations have an extremely poor prognosis most these are missense mutations. Here, we report that, in contrast to the mixed AML T cell malignancy developed NrasG12D/+ p53-/- (NP-/-) mice, p53R172H/+ (NPmut) mice rapidly inflammation-associated AML. Under inflammatory conditions, NPmut hematopoietic stem progenitor cells (HSPCs) displayed imbalanced myelopoiesis...
ABSTRACT Hematopoietic stem cells (HSCs) with multilineage potential are critical for effective T cell reconstitution and restoration of the adaptive immune system after allogeneic Cell Transplantation (allo-HCT). The Kit lo subset HSCs is enriched multipotential precursors, 1, 2 but their T-cell lineage has not been well-characterized. We therefore studied thymic reconstituting HSCs. Using a preclinical allo-HCT model, we demonstrate that support better recovery, resulting in improved...
Abstract Resistance to chimeric antigen receptor (CAR) T cell therapy develops through multiple mechanisms including antigen-loss escape and tumor-induced immune suppression. Expression of CARs may overcome multi-antigen-loss escape. Similarly, expression switch receptors that convert inhibitory checkpoint signals into positive costimulatory enhance CAR activity in the tumor microenvironment. Engineering features one product, however, is limited by transgene packaging constraints current...
Abstract Multiple myeloma (MM) is characterized by clonal expansion of malignant plasma cells (PCs) and aberrant production monoclonal immunoglobulin detected as an M spike using serum protein electrophoresis. In the United States, MM represents ~15% hematologic malignancies one few cancers increasing in incidence (e.g., 14,400 1996 to 30,330 2016, from SEER). Previously, a Vk*MYC mouse model was described, which AID-dependent activation MYC transgene germinal center (GC) B catalyzes highly...
Abstract Multiple myeloma (MM) is a malignant plasma cell cancer. Mutations in RAS pathway genes are prevalent advanced and proteasome inhibitor (PI) refractory MM. As such, we recently developed VQ MM mouse model recapitulating human advanced/high-risk Using lines conducted re-purpose screen of 147 FDA-approved anti-cancer drugs with or without trametinib (Tra), MEK inhibitor. Consistent its high-risk molecular feature, displayed reduced responses to PIs de novo resistance the Bcl2...